<SEC-DOCUMENT>0001999371-25-017369.txt : 20251110
<SEC-HEADER>0001999371-25-017369.hdr.sgml : 20251110
<ACCEPTANCE-DATETIME>20251110162647
ACCESSION NUMBER:		0001999371-25-017369
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20251110
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251110
DATE AS OF CHANGE:		20251110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tonix Pharmaceuticals Holding Corp.
		CENTRAL INDEX KEY:			0001430306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				261434750
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36019
		FILM NUMBER:		251466621

	BUSINESS ADDRESS:	
		STREET 1:		26 MAIN STREET, SUITE 101
		CITY:			CHATHAM
		STATE:			NJ
		ZIP:			07928
		BUSINESS PHONE:		212-980-9155

	MAIL ADDRESS:	
		STREET 1:		26 MAIN STREET, SUITE 101
		CITY:			CHATHAM
		STATE:			NJ
		ZIP:			07928

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TAMANDARE EXPLORATIONS INC.
		DATE OF NAME CHANGE:	20080320
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tnxp-8k_111025.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:tnxp="http://tonixpharma.com/20251110">
<head>
     <title>Current Report</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_03D_tnxp_tonixpharma.com_20251110 -->
<!-- Field: Set; Name: xdx; ID: xdx_040_20251110_20251110 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05B_edei%2D%2DEntityCentralIndexKey_0001430306 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-11-10" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-11-10" id="Fact000004" name="dei:EntityCentralIndexKey">0001430306</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="tnxp-20251110.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-11-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-10</xbrli:startDate>
        <xbrli:endDate>2025-11-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"></p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNITED STATES&#160;</b></p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION&#160;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>


<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORM <span id="xdx_908_edei--DocumentType_c20251110__20251110_zzBgjrmZxHc4"><ix:nonNumeric contextRef="AsOf2025-11-10" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Date of report (date of earliest event reported):
<span id="xdx_90B_edei--DocumentPeriodEndDate_c20251110__20251110_zttPEPdTnDPe"><ix:nonNumeric contextRef="AsOf2025-11-10" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">November 10, 2025</ix:nonNumeric></span></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 16pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="xdx_905_edei--EntityRegistrantName_c20251110__20251110_z4D2MtCbSgnf"><ix:nonNumeric contextRef="AsOf2025-11-10" id="Fact000011" name="dei:EntityRegistrantName">TONIX PHARMACEUTICALS HOLDING CORP.</ix:nonNumeric></span></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(Exact name of registrant as specified in its charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityIncorporationStateCountryCode_c20251110__20251110_zBs36b9CYO9g"><ix:nonNumeric contextRef="AsOf2025-11-10" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityFileNumber_c20251110__20251110_zIN2pPqKpMEf"><ix:nonNumeric contextRef="AsOf2025-11-10" id="Fact000013" name="dei:EntityFileNumber">001-36019</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityTaxIdentificationNumber_c20251110__20251110_zSWmm3IuJW15"><ix:nonNumeric contextRef="AsOf2025-11-10" id="Fact000014" name="dei:EntityTaxIdentificationNumber">26-1434750</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(State or Other Jurisdiction&#160;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>of Incorporation)&#160;</b></p></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(Commission&#160;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>File Number)</b></p></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(IRS Employer&#160;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Identification No.)</b>&#160;</p></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><b><span id="xdx_90B_edei--EntityAddressAddressLine1_c20251110__20251110_zCKiMVGUH9v5"><ix:nonNumeric contextRef="AsOf2025-11-10" id="Fact000015" name="dei:EntityAddressAddressLine1">26 Main Street</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressCityOrTown_c20251110__20251110_zoJCyL4fA652"><ix:nonNumeric contextRef="AsOf2025-11-10" id="Fact000016" name="dei:EntityAddressCityOrTown">Chatham</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressStateOrProvince_c20251110__20251110_ziVjxUUamu0j"><ix:nonNumeric contextRef="AsOf2025-11-10" format="ixt-sec:stateprovnameen" id="Fact000017" name="dei:EntityAddressStateOrProvince">New Jersey</ix:nonNumeric></span>,
<span id="xdx_90F_edei--EntityAddressPostalZipCode_c20251110__20251110_zNBSJeJrgm48"><ix:nonNumeric contextRef="AsOf2025-11-10" id="Fact000018" name="dei:EntityAddressPostalZipCode">07928</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices) (Zip Code)</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">Registrant&#8217;s telephone number, including area
code: <b><span id="xdx_90C_edei--CityAreaCode_c20251110__20251110_zTHk6jnWLQu9"><ix:nonNumeric contextRef="AsOf2025-11-10" id="Fact000019" name="dei:CityAreaCode">(862)</ix:nonNumeric></span> <span id="xdx_90C_edei--LocalPhoneNumber_c20251110__20251110_zVCbeX64XFO3"><ix:nonNumeric contextRef="AsOf2025-11-10" id="Fact000020" name="dei:LocalPhoneNumber">799-8599</ix:nonNumeric></span></b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span id="xdx_904_edei--WrittenCommunications_c20251110__20251110_zikao4rfqrgd"><ix:nonNumeric contextRef="AsOf2025-11-10" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span> Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_909_edei--SolicitingMaterial_c20251110__20251110_zf1mPuv8ZFw8"><ix:nonNumeric contextRef="AsOf2025-11-10" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span> Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_903_edei--PreCommencementTenderOffer_c20251110__20251110_zwACWec99H2k"><ix:nonNumeric contextRef="AsOf2025-11-10" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span> Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_902_edei--PreCommencementIssuerTenderOffer_c20251110__20251110_z3qs10kogga4"><ix:nonNumeric contextRef="AsOf2025-11-10" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span> Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">Securities registered pursuant
to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 33%; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 33%; padding-left: 5.4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--Security12bTitle_c20251110__20251110_zAXRfWeatOeh"><ix:nonNumeric contextRef="AsOf2025-11-10" id="Fact000025" name="dei:Security12bTitle">Common Stock</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--TradingSymbol_c20251110__20251110_z2ZyWz1pazDb"><ix:nonNumeric contextRef="AsOf2025-11-10" id="Fact000026" name="dei:TradingSymbol">TNXP</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The<span id="xdx_90E_edei--SecurityExchangeName_c20251110__20251110_zjGJU8jH9q7l"> <ix:nonNumeric contextRef="AsOf2025-11-10" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric> </span>Capital Market</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">Emerging growth company <span id="xdx_90E_edei--EntityEmergingGrowthCompany_c20251110__20251110_zSXzVwwpawy5"><ix:nonNumeric contextRef="AsOf2025-11-10" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section&#160;13(a) of the Exchange Act. &#9744;</p>



<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: white">
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 2.02</b></span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; width: 91%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results of Operations and Financial Condition</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On November
10, 2025, Tonix Pharmaceuticals Holding Corp. (the &#8220;Company&#8221;) announced its operating results for the quarter ended September
30, 2025. A copy of the press release that discusses these matters is filed as Exhibit 99.01 to, and incorporated by reference in, this
report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 9.01</b></span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; width: 91%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Statements and Exhibits.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; vertical-align: top; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; width: 1%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 13%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exhibit</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>No.</b></p></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; width: 1%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 83%; font: 12pt Arial, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description.</b></span></td></tr>
  <tr>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><a href="ex99-01.htm">99.01</a></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">104</p></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Press Release of the Company, dated November 10, 2025</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><b>SIGNATURE</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirement of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TONIX PHARMACEUTICALS HOLDING CORP.</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: November 10, 2025</span></td>
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </span></td>
    <td style="border-bottom: black 1pt solid; width: 23%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Bradley Saenger</span></td>
    <td style="width: 23%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bradley Saenger</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>

    <!-- Field: /Page -->



<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KgkAQhZ/Adxj2OmxV8sLLpCKyEInodskxlnRHZrcfH6m3bFOiYWCYOec7I8RMbGitW2Q4L6sCjtj1rXIIFTbIaC7oHfl2l4GfFV61dayMG9cfmJNn0DNpmCh/H50PbbHOIIrmMpnHC5BpJhMo9yL46jmZRtdonFYtKFNDydSzRqd4mBKO6kWGumH8dEK2moyPC+UkvyGWUQwHeqgn8c1CUeQimI0ViA3Tvfeu1cuh+ZKwarHz7+xE/zv4AMhrSlc= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.01
<SEQUENCE>2
<FILENAME>ex99-01.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<!-- Field: Rule-Page --><DIV STYLE="margin-top: 10pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0"><A HREF="tnxp-8k_111025.htm">TONIX PHARMACEUTICALS HOLDING CORP 8-K</A></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0"><B>Exhibit 99.01</B>&nbsp;</P>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;<IMG SRC="tnxp-logo.jpg" ALT=""></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"></P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Tonix Pharmaceuticals Reports Third Quarter 2025
Financial Results and Operational Highlights</B></P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: center"><I>Tonmya&trade; (cyclobenzaprine HCl sublingual tablets)
for the treatment of fibromyalgia set to launch in November</I></P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: center"><I>Tonmya is the first new FDA-approved medicine for
fibromyalgia in more than 15 years</I></P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: center"><I>Cash and cash equivalents of $190.1 million reported
as of September 30, 2025; current cash runway expected to fund operations into the first quarter of 2027</I></P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify">CHATHAM, N.J., November 10, 2025 (GLOBE NEWSWIRE) &mdash;
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (&ldquo;Tonix&rdquo; or the &ldquo;Company&rdquo;), a fully-integrated commercial biotechnology
company today announced financial results for the third quarter ended September 30, 2025, and provided an overview of recent operational
highlights.</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify">&ldquo;Following U.S. Food and Drug Administration
(FDA) approval of Tonmya<SUP>TM</SUP>, we are focused on execution of the U.S. launch later this month to bring the first new treatment
option for fibromyalgia to patients and&nbsp;clinicians in more than 15 years,&rdquo; said Seth Lederman, M.D., Chief Executive Officer
of Tonix Pharmaceuticals. &ldquo;We have built the commercial infrastructure, market access capabilities, and brand awareness to position
Tonmya for a strong launch and sustainable market presence.&rdquo;</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify">Dr. Lederman continued, &ldquo;Turning to our pipeline,
we were excited to in-license TNX-4800, a Phase 2-ready, long-acting human monoclonal antibody for the seasonal prevention of Lyme disease,
and to announce a collaboration with Massachusetts General Hospital to conduct an investigator-initiated Phase 2 study of TNX-1500 for
the prevention of kidney transplant rejection. Our priorities are clear: launch Tonmya successfully, advance our pipeline strategically,
and drive sustainable growth that benefits patients and shareholders.&rdquo;</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Commercial Updates</B></P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">Tonmya (cyclobenzaprine HCl sublingual tablets)
2.8 mg: a centrally acting, non-opioid analgesic for the treatment of fibromyalgia in adults</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 9pt  Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family:  Times New Roman, Times, Serif; font-size: 10pt">In August, the FDA approved Tonmya,
the first new fibromyalgia therapy in more than 15 years.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 9pt  Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family:  Times New Roman, Times, Serif; font-size: 10pt">In September, the Company established
the wholesale acquisition cost (WAC) for Tonmya.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 9pt  Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family:  Times New Roman, Times, Serif; font-size: 10pt">In October, Tonix announced the
commercial launch of Tonmya will commence before the end of November. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 9pt  Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family:  Times New Roman, Times, Serif; font-size: 10pt">90 Tonmya sales representatives
have been in the field for over a month, in preparation for the November launch. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 9pt  Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family:  Times New Roman, Times, Serif; font-size: 10pt">Tonix has contracted with its
existing wholesalers and specialty pharmacies for the distribution of Tommya. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 9pt  Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family:  Times New Roman, Times, Serif; font-size: 10pt">Tonix has also contracted with
companies to assist with prescription fulfillment and patient access.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 9pt  Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family:  Times New Roman, Times, Serif; font-size: 10pt">The Company strengthened its
commercial organization with the appointment of Ganesh Kamath as Head of Market Access to lead pricing, payer strategy, and reimbursement
for the Tonmya launch. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">Tosymra&reg; (sumatriptan
nasal spray) 10 mg: approved treatment of acute migraine in adults</P>

<P STYLE="font: 9pt  Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family:  Times New Roman, Times, Serif; font-size: 10pt">Effective January 1, 2026, Tosymra has preferred exclusive
placement on a payer formulary representing approximately 16 million covered lives. </FONT></P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Pipeline Updates</B></P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">TNX-102 SL (cyclobenzaprine HCl sublingual tablets)
2.8 mg: in development for major depressive disorder (MDD)</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 9pt  Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family:  Times New Roman, Times, Serif; font-size: 10pt">In August, Tonix held a positive
Type B Pre-Investigational New Drug (IND) meeting with the FDA regarding TNX-102 SL for MDD. </FONT></TD></TR></TABLE>

<P STYLE="font: 9pt  Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family:  Times New Roman, Times, Serif; font-size: 10pt">In October, the Company filed the IND, and, upon receiving
IND clearance, Tonix intends to initiate a Phase 2 study by mid-year 2026.<BR>
<BR>
</FONT></P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">TNX-1500 (dimeric Fc modified anti-CD40L, humanized
monoclonal antibody [mAb]): third generation anti-CD40L under investigation for prophylaxis of kidney transplant rejection, with the potential
to also be a treatment for autoimmune disorders.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 9pt  Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family:  Times New Roman, Times, Serif; font-size: 10pt">In October, Tonix presented an
update at the <I>Japan Society for Transplantation</I> annual congress, highlighting Phase 1 safety and biomarker results and outlining
next steps toward Phase 2 evaluation in allo-transplantation.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 9pt  Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family:  Times New Roman, Times, Serif; font-size: 10pt">In November, Tonix announced
a collaboration with Massachusetts General Hospital to advance a Phase 2 open-label, investigator-initiated, clinical trial of TNX-1500
in kidney transplant recipients in 1H2026.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify">TNX-4800 (anti-OspA mAb): long-acting human mAb in
development for the prevention of Lyme disease</P>

<P STYLE="font: 9pt  Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September, Tonix announced in-licensing
worldwide rights to TNX-4800, from UMass Chan Medical School. TNX-4800 is a fully human mAb that targets and kills <I>Borrelia burgdorferi</I>
inside infected deer ticks when they have bitten treated animals and ingested their blood.</FONT></P>

<P STYLE="font: 9pt  Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 11pt">Adaptive Phase 2/3 study will test whether TNX-4800 protects humans by killing B. burgdorferi <FONT STYLE="color: windowtext">inside
infected deer ticks when they have bitten treated humans and ingested their blood.</FONT></FONT></P>

<P STYLE="font: 9pt  Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family:  Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">Th</FONT><FONT STYLE="font-family:  Times New Roman, Times, Serif; font-size: 10pt">ere
are currently no FDA-approved vaccines or prophylactics to protect against Lyme Disease.</FONT></P>

<P STYLE="font: 9pt  Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family:  Times New Roman, Times, Serif; font-size: 10pt">Tonix plans to initiate the adaptive Phase 2/3 study during
tick season in 2027.</FONT></P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">TNX-2900 (intranasal potentiated oxytocin): in
development for Prader-Willi syndrome</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 9pt  Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family:  Times New Roman, Times, Serif; font-size: 10pt">In September, Tonix announced
plans to initiate a Phase 2, randomized, double-blind, placebo-controlled trial in 2H 2026 in children and adolescents. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 9pt  Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family:  Times New Roman, Times, Serif; font-size: 10pt">TNX-2900 has Orphan Drug designation
as well as Rare Pediatric Disease designation that could make Tonix eligible for a <I>Priority Review Voucher</I> upon approval.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Financials</B></P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify">As of<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>September<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>30,<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>2025,
Tonix had $190.1<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>million in cash and cash equivalents, compared with
$98.8<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>million as of<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>December
31, 2024<FONT STYLE="font-family:  Times New Roman, Times, Serif">.</FONT> Net cash used in operations was approximately<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>$60.2<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>million
for the nine months ended September 30, 2025, compared to $46.3<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>million
for the same period in 2024.</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on its current operating plan, the Company believes
its cash on hand as of September<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>30<FONT STYLE="font-family:  Times New Roman, Times, Serif">,
2025</FONT>, together with $34.7<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>million in net proceeds received
from equity offerings during the fourth quarter<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>2025, will fund planned
operating and capital expenditures into the first quarter<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>of<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>2027.</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Third Quarter 2025 Financial Results</I></P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify">Net product revenue for the three months ended September
30,<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>2025 was approximately $3.3<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>million,
compared to $2.8<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>million for the same period in<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>2024;
revenue reflected combined net sales of Zembrace&reg;<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>SymTouch&reg;
(sumatriptan injection) and Tosymra&reg; (sumatriptan nasal spray). Cost of sales for the three months ended September 30,<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>2025
was approximately $1.4<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>million, compared to $1.6<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>million
for the same period in<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>2024.</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify"><BR>
Research and development expenses for the three months ended September 30,<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>2025
were $9.3<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>million, compared to $9.1<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>million
for the same period in<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>2024. The increase was predominately due to
increased manufacturing expenses of $2.3 million, offset by a reduction in clinical expenses of $2.1 million, as a result of pipeline
prioritization period over period.</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify">Selling, general and administrative expenses for the
three months ended September 30,<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;</FONT>2025 were $25.7 million, compared
to $7.7 million in<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;</FONT>2024. The increase is predominately due to spending
on sales and marketing relating to Tonmya.</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify"><BR>
Net loss available to common stockholders was $32.0<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>million, or $3.59
per share (basic and diluted), for the third quarter<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>2025, compared
to a net loss of $14.2<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>million, or $22.68 per share, for the same
period in<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>2024. The basic and diluted weighted-average common shares
outstanding for the third quarter<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>2025 were 8,922,792, compared to
626,669 for the same period in<FONT STYLE="font-family:  Times New Roman, Times, Serif">&#8239;</FONT>2024.</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Tonix Pharmaceuticals Holding Corp.*</B></P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family:  Times New Roman, Times, Serif; color: windowtext">Tonix
Pharmaceuticals is a fully-integrated biotechnology company with marketed products and a pipeline of development candidates. Tonix has
received FDA approval for Tonmya<SUP>TM</SUP>, a first-in-class, non-opioid analgesic medicine for the treatment of fibromyalgia, a chronic
pain condition that affects millions of adults. This marks the first approval for a new prescription medicine for fibromyalgia in more
than 15 years. Tonix also markets two treatments for acute migraine in adults: </FONT><FONT STYLE="font-family:  Times New Roman, Times, Serif">Zembrace&reg;</FONT>&#8239;<FONT STYLE="font-family:  Times New Roman, Times, Serif">SymTouch&reg;
and Tosymra&reg;<FONT STYLE="color: windowtext">. Tonix&rsquo;s development portfolio is focused on central nervous system (CNS) disorders,
immunology, immuno-oncology, rare disease and infectious disease. TNX-102 SL is being developed to treat acute stress reaction and acute
stress disorder under an Investigator-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department
of Defense (DoD). TNX-102 SL is also in development for major depressive disorder. Tonix&rsquo;s immunology development portfolio consists
of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal
antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune
diseases. Tonix&rsquo;s rare disease portfolio includes TNX-2900, intranasal oxytocin potentiated with magnesium, in development for Prader-Willi
syndrome. Tonix&rsquo;s infectious disease portfolio includes TNX-801, a vaccine in development for mpox and smallpox, as well as TNX-4800,
a monoclonal antibody for the seasonal prevention of Lyme Disease. Finally, TNX-4200 for which Tonix has a contract with the U.S. DoD&rsquo;s
Defense Threat Reduction Agency (DTRA) for up to $34 million over five years, is a small molecule broad-spectrum antiviral agent targeting
CD45 for the prevention or treatment of high lethality infections to improve the medical readiness of military personnel in biological
threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md.</FONT></FONT></P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">* Tonix&rsquo;s product development candidates
are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">This press release and further information
about Tonix can be found at&nbsp;<FONT STYLE="color: Blue"><U>www.tonixpharma.com</U></FONT>.</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt Segoe UI, Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking
words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;forecast,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; and
&ldquo;intend,&rdquo; among others. These forward-looking statements are based on Tonix's current expectations and actual results could
differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking
statements. These factors include, but are not limited to, risks related to the failure to successfully launch and commercialize Tonmya
and any of our approved products; risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations;
risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties
of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development
efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant
risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update
or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year
ended December 31, 2024, as filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on March 18, 2025, and periodic
reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such
risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
<P STYLE="margin: 0">&nbsp;</P>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TONIX PHARMACEUTICALS HOLDING CORP.</b>&#160;<BR>

<b>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</b><BR>
<b>(In Thousands, Except Share and Per Share Amounts)</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(unaudited)</b>&#160;</p>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <TD COLSPAN="2" STYLE="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <TD COLSPAN="2" STYLE="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><P STYLE="font-size: 10pt"><B>Three Months Ended<BR>
September
30,</B></P></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><P STYLE="font-size: 10pt"><B>Nine Months Ended<BR>
September
30,</B></P></td>
    <td style="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><P STYLE="font-size: 10pt"><b>2025</b></P></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><P STYLE="font-size: 10pt"><b>2024</b></P></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><P STYLE="font-size: 10pt"><b>2025</b></P></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><P STYLE="font-size: 10pt"><b>2024</b></P></td>
    <td style="padding-bottom: 1pt">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom">
    <td><P STYLE="font-size: 10pt">REVENUE:</P></td>
    <td>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; padding-left: 10pt; text-indent: -10pt"><P STYLE="font-size: 10pt">Product revenue, net</P></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><P STYLE="font-size: 10pt">$</P></td>
    <td style="width: 12%; text-align: right"><P STYLE="font-size: 10pt">3,290</P></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><P STYLE="font-size: 10pt">$</P></td>
    <td style="width: 12%; text-align: right"><P STYLE="font-size: 10pt">2,822</P></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><P STYLE="font-size: 10pt">$</P></td>
    <td style="width: 12%; text-align: right"><P STYLE="font-size: 10pt">7,717</P></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><P STYLE="font-size: 10pt">$</P></td>
    <td style="width: 12%; text-align: right"><P STYLE="font-size: 10pt">7,512</P></td>
    <td style="width: 1%">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-indent: -10pt"><P STYLE="font-size: 10pt">COSTS AND EXPENSES:</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><P STYLE="font-size: 10pt">Cost of revenue</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><P STYLE="font-size: 10pt">1,367</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><P STYLE="font-size: 10pt">1,555</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><P STYLE="font-size: 10pt">5,582</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><P STYLE="font-size: 10pt">6,582</P></td>
    <td>&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-indent: -10pt"><P STYLE="font-size: 10pt">Research and development</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><P STYLE="font-size: 10pt">9,289</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><P STYLE="font-size: 10pt">9,114</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><P STYLE="font-size: 10pt">27,545</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><P STYLE="font-size: 10pt">31,675</P></td>
    <td>&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><P STYLE="font-size: 10pt">Selling, general and administrative</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><P STYLE="font-size: 10pt">25,701</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><P STYLE="font-size: 10pt">7,707</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><P STYLE="font-size: 10pt">52,007</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><P STYLE="font-size: 10pt">24,519</P></td>
    <td>&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><P STYLE="font-size: 10pt">Asset impairment charges</P></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><P STYLE="font-size: 10pt"><P STYLE="-sec-ix-hidden: xdx2ixbrl0201">&#8212;</P></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><P STYLE="font-size: 10pt"><P STYLE="-sec-ix-hidden: xdx2ixbrl0202">&#8212;</P></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><P STYLE="font-size: 10pt"><P STYLE="-sec-ix-hidden: xdx2ixbrl0203">&#8212;</P></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><P STYLE="font-size: 10pt">58,957</P></td>
    <td style="padding-bottom: 1pt">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><P STYLE="font-size: 10pt">36,357</P></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><P STYLE="font-size: 10pt">18,376</P></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><P STYLE="font-size: 10pt">85,134</P></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><P STYLE="font-size: 10pt">121,733</P></td>
    <td style="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-indent: -10pt">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><P STYLE="font-size: 10pt">Operating loss</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><P STYLE="font-size: 10pt">(33,067</P></td>
    <td><P STYLE="font-size: 10pt">)</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><P STYLE="font-size: 10pt">(15,554</P></td>
    <td><P STYLE="font-size: 10pt">)</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><P STYLE="font-size: 10pt">(77,417</P></td>
    <td><P STYLE="font-size: 10pt">)</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><P STYLE="font-size: 10pt">(114,221</P></td>
    <td><P STYLE="font-size: 10pt">)</P></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-indent: -10pt">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><P STYLE="font-size: 10pt">Grant income</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><P STYLE="font-size: 10pt">982</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><P STYLE="font-size: 10pt">1,668</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><P STYLE="font-size: 10pt">2,941</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><P STYLE="font-size: 10pt">1,668</P></td>
    <td>&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-indent: -10pt"><P STYLE="font-size: 10pt">Gain on change in fair value of warrant liabilities</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><P STYLE="font-size: 10pt">6,150</P></td>
    <td>&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><P STYLE="font-size: 10pt">Loss on extinguishment of debt</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><P STYLE="font-size: 10pt">&#8212;</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><P STYLE="font-size: 10pt">&#8212;</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><P STYLE="font-size: 10pt">(2,092)</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><P STYLE="font-size: 10pt">&#8212;</P></td>
    <td>&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-indent: -10pt"><P STYLE="font-size: 10pt">Interest income</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><P STYLE="font-size: 10pt">1,231</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><P STYLE="font-size: 10pt">18</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><P STYLE="font-size: 10pt">2,802</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><P STYLE="font-size: 10pt">21</P></td>
    <td>&nbsp;</td></tr>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt">Interest expense</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><P STYLE="-sec-ix-hidden: xdx2ixbrl0236">&#8212;</P></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">(301</td>
    <td>)</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">(89)</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">(954</td>
    <td>)</td></tr>

<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><P STYLE="font-size: 10pt">Other expense, net</P></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><P STYLE="font-size: 10pt">(1,156)</P></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><P STYLE="font-size: 10pt">(44</P></td>
    <td style="padding-bottom: 1pt"><P STYLE="font-size: 10pt">)</P></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><P STYLE="font-size: 10pt">(3,256</P></td>
    <td style="padding-bottom: 1pt"><P STYLE="font-size: 10pt">)</P></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><P STYLE="font-size: 10pt">(592</P></td>
    <td style="padding-bottom: 1pt"><P STYLE="font-size: 10pt">)</P></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt"><P STYLE="font-size: 10pt">Net loss available to common stockholders</P></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double"><P STYLE="font-size: 10pt">$</P></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><P STYLE="font-size: 10pt">(32,010</P></td>
    <td style="padding-bottom: 2.5pt"><P STYLE="font-size: 10pt">)</P></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double"><P STYLE="font-size: 10pt">$</P></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><P STYLE="font-size: 10pt">(14,213</P></td>
    <td style="padding-bottom: 2.5pt"><P STYLE="font-size: 10pt">)</P></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double"><P STYLE="font-size: 10pt">$</P></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><P STYLE="font-size: 10pt">(77,111</P></td>
    <td style="padding-bottom: 2.5pt"><P STYLE="font-size: 10pt">)</P></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double"><P STYLE="font-size: 10pt">$</P></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><P STYLE="font-size: 10pt">(107,928</P></td>
    <td style="padding-bottom: 2.5pt"><P STYLE="font-size: 10pt">)</P></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-indent: -10pt; padding-bottom: 2.5pt"><P STYLE="font-size: 10pt">Net loss per common share, basic and diluted</P></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double"><P STYLE="font-size: 10pt">$</P></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><P STYLE="font-size: 10pt">(3.59</P></td>
    <td style="padding-bottom: 2.5pt"><P STYLE="font-size: 10pt">)</P></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double"><P STYLE="font-size: 10pt">$</P></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><P STYLE="font-size: 10pt">(22.68</P></td>
    <td style="padding-bottom: 2.5pt"><P STYLE="font-size: 10pt">)</P></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double"><P STYLE="font-size: 10pt">$</P></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><P STYLE="font-size: 10pt">(10.42</P></td>
    <td style="padding-bottom: 2.5pt"><P STYLE="font-size: 10pt">)</P></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double"><P STYLE="font-size: 10pt">$</P></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><P STYLE="font-size: 10pt">(466.17</P></td>
    <td style="padding-bottom: 2.5pt"><P STYLE="font-size: 10pt">)</P></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt"><P STYLE="font-size: 10pt">Weighted average common shares outstanding, basic and diluted</P></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><P STYLE="font-size: 10pt">8,922,792</P></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><P STYLE="font-size: 10pt">626,669</P></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><P STYLE="font-size: 10pt">7,403,400</P></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><P STYLE="font-size: 10pt">231,523</P></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TONIX PHARMACEUTICALS HOLDING CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONDENSED CONSOLIDATED BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(In Thousands)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt  Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>September 30, <BR>
2025</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December 31,<BR>
2024<SUP>1</SUP></B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assets</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 72%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">190,055</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">98,776</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable, net</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,481</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,683</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,729</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,408</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and other</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,806</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,135</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total current assets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">208,071</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">119,002</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other non-current assets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44,369</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43,888</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total assets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">252,440</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">162,890</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liabilities and stockholders' equity</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total liabilities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,297</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,332</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders' equity</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">231,143</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">139,558</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total liabilities and stockholders' equity</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">252,440</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">162,890</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><SUP>1</SUP>The condensed consolidated balance sheet for the year
ended December 31, 2024 has been derived from the audited financial statements but do not include all of the information and footnotes
required by accounting principles generally accepted in the United States for complete financial statements.</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Investor Contact</B>s</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0">Jessica Morris<BR>
Tonix Pharmaceuticals&nbsp;<BR>
<FONT STYLE="color: Blue">investor.relations@tonixpharma.com</FONT>&nbsp;<BR>
(862) 799-8599&nbsp;</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; background-color: white">Brian Korb&nbsp;<BR>
astr partners&nbsp;<BR>
<FONT STYLE="color: #242424">(917) 653-5122&nbsp;</FONT></P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; background-color: white; color: #0563C1"><FONT STYLE="color: Blue">brian.korb@astrpartners.com&nbsp;</FONT></P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0; background-color: white; color: #242424">&nbsp;</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0"><B>Media Contacts<BR>
</B>Mary Ann Ondish</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0">Tonix Pharmaceuticals<BR>
<FONT STYLE="color: Blue">maryann.ondish@tonixpharma.com</FONT></P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt  Times New Roman, Times, Serif; margin: 0">Ray Jordan&nbsp;<BR>
Putnam Insights&nbsp;<BR>
<FONT STYLE="color: Blue">ray@putnaminsights.com&nbsp;</FONT><BR>
&nbsp;</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>INDICATION</B></P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">TONMYA is indicated for the treatment of fibromyalgia
in adults.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>CONTRAINDICATIONS</B></P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">TONMYA is contraindicated:</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">In patients with hypersensitivity to cyclobenzaprine
or any inactive ingredient in TONMYA. Hypersensitivity reactions may manifest as an anaphylactic reaction, urticaria, facial and/or tongue
swelling, or pruritus. Discontinue TONMYA if a hypersensitivity reaction is suspected.</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">With concomitant use of monoamine oxidase (MAO)
inhibitors or within 14 days after discontinuation of an MAO inhibitor. Hyperpyretic crisis seizures and deaths have occurred in patients
who received cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitors drugs.</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">During the acute recovery phase of myocardial
infarction, and in patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure.</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">In patients with hyperthyroidism.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>WARNINGS AND PRECAUTIONS</B></P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">Embryofetal toxicity: Based on animal data, TONMYA
may cause neural tube defects when used two weeks prior to conception and during the first trimester of pregnancy. Advise females of reproductive
potential of the potential risk and to use effective contraception during treatment and for two weeks after the final dose. Perform a
pregnancy test prior to initiation of treatment with TONMYA to exclude use of TONMYA during the first trimester of pregnancy.</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">Serotonin syndrome: Concomitant use of TONMYA
with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants,
tramadol, bupropion, meperidine, verapamil, or MAO inhibitors increases the risk of serotonin syndrome, a potentially life-threatening
condition. Serotonin syndrome symptoms may include mental status changes, autonomic instability, neuromuscular abnormalities, and/or
gastrointestinal symptoms. Treatment with TONMYA and any concomitant serotonergic agent should be discontinued immediately if serotonin
syndrome symptoms occur and supportive <B>symptomatic treatment should be initiated. </B>If concomitant treatment with TONMYA and other
serotonergic drugs is clinically warranted, careful observation is advised, particularly during treatment initiation or dosage increases.&nbsp;</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">Tricyclic antidepressant-like adverse reactions:
Cyclobenzaprine is structurally related to TCAs. TCAs have been reported to produce arrhythmias, sinus tachycardia, prolongation of the
conduction time leading to myocardial infarction and stroke. If clinically significant central nervous system (CNS) symptoms develop,
consider discontinuation of TONMYA. Caution should be used when TCAs are given to patients with a history of seizure disorder, because
TCAs may lower the seizure threshold. Patients with a history of seizures should be monitored during TCA use to identify recurrence of
seizures or an increase in the frequency of seizures.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">Atropine-like effects: Use with caution in patients
with a history of urinary retention, angle-closure glaucoma, increased intraocular pressure, and in patients taking anticholinergic drugs.</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">CNS depression and risk of operating a motor vehicle
or hazardous machinery: TONMYA monotherapy may cause CNS depression. Concomitant use of TONMYA with alcohol, barbiturates, or other CNS
depressants may increase the risk of CNS depression. Advise patients not to operate a motor vehicle or dangerous machinery until they
are reasonably certain that TONMYA therapy will not adversely affect their ability to engage in such activities.</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">Oral mucosal adverse reactions: In clinical studies
with TONMYA, oral mucosal adverse reactions occurred more frequently in patients treated with TONMYA compared to placebo. Advise patients
to moisten the mouth with sips of water before administration of TONMYA to reduce the risk of oral sensory changes (hypoesthesia). Consider
discontinuation of TONMYA if severe reactions occur.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>ADVERSE REACTIONS</B></P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">The most common adverse reactions (incidence <FONT STYLE="font-family: DengXian">&ge;</FONT>2%
and at a higher incidence in TONMYA-treated patients compared to placebo-treated patients) were oral hypoesthesia, oral discomfort, abnormal
product taste, somnolence, oral paresthesia, oral pain, fatigue, dry mouth, and aphthous ulcer.</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>DRUG INTERACTIONS</B></P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">MAO inhibitors: Life-threatening interactions
may occur.</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">Other serotonergic drugs: Serotonin syndrome has
been reported.</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">CNS depressants: CNS depressant effects of alcohol,
barbiturates, and other CNS depressants may be enhanced.</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">Tramadol: Seizure risk may be enhanced.</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">Guanethidine or other similar acting drugs: The
antihypertensive action of these drugs may be blocked.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>USE IN SPECIFIC POPULATIONS</B></P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">Pregnancy: Based on animal data, TONMYA may cause
fetal harm when administered to a pregnant woman. The limited amount of available observational data on oral cyclobenzaprine use in pregnancy
is of insufficient quality to inform a TONMYA-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
Advise pregnant women about the potential risk to the fetus with maternal exposure to TONMYA and to avoid use of TONMYA two weeks prior
to conception and through the first trimester of pregnancy. Report pregnancies to the Tonix Medicines, Inc., adverse-event reporting line
at 1-888-869-7633 (1-888-TNXPMED).</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">Lactation: A small number of published cases report
the transfer of cyclobenzaprine into human milk in low amounts, but these data cannot be confirmed. There are no data on the effects of
cyclobenzaprine on a breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should
be considered along with the mother&rsquo;s clinical need for TONMYA and any potential adverse effects on the breastfed child from TONMYA
or from the underlying maternal condition.</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">Pediatric use: The safety and effectiveness of
TONMYA have not been established.</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">Geriatric patients: Of the total number of TONMYA-treated
patients in the clinical trials in adult patients with fibromyalgia, none were 65 years of age and older. Clinical trials of TONMYA did
not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult
patients.</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">Hepatic impairment: The recommended dosage of
TONMYA in patients with mild hepatic impairment (HI) (Child Pugh A) is 2.8 mg once daily at bedtime, lower than the recommended dosage
in patients with normal hepatic function. The use of TONMYA is not recommended in patients with moderate HI (Child Pugh B) or severe HI
(Child Pugh C). Cyclobenzaprine exposure (AUC) was increased in patients with mild HI and moderate HI compared to subjects with normal
hepatic function, which may increase the risk of TONMYA-associated adverse reactions.</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Please see additional safety information in
the full Prescribing Information.</B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>To report suspected adverse reactions, contact
Tonix Medicines, Inc. at 1-888-869-7633, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</B></P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Indication and Usage</B></P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">Zembrace<SUP>&reg;</SUP>&nbsp;SymTouch<SUP>&reg;</SUP>&nbsp;(sumatriptan
succinate) injection (Zembrace) and Tosymra<SUP>&reg;</SUP>&nbsp;(sumatriptan) nasal spray are prescription medicines used to treat acute
migraine headaches with or without aura in adults who have been diagnosed with migraine.</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">Zembrace and Tosymra are not used to prevent migraines.
It is not known if Zembrace or Tosymra are safe and effective in children under 18 years of age.</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Important Safety Information</B></P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Zembrace and Tosymra can cause serious side
effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs
of a heart attack:</B></P>

<UL STYLE="margin-top: 0in; list-style-type: disc">

<LI STYLE="text-align: justify; margin: 0">discomfort in the center of your chest that lasts for more than a few minutes or goes away
and comes back</LI>

<LI STYLE="text-align: justify; margin: 0">severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw</LI>

<LI STYLE="text-align: justify; margin: 0">pain or discomfort in your arms, back, neck, jaw or stomach</LI>

<LI STYLE="text-align: justify; margin: 0">shortness of breath with or without chest discomfort</LI>

<LI STYLE="text-align: justify; margin: 0">breaking out in a cold sweat</LI>

<LI STYLE="text-align: justify; margin: 0">nausea or vomiting</LI>

<LI STYLE="text-align: justify; margin: 0">feeling lightheaded</LI>

</UL>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">Zembrace and Tosymra are not for people with risk
factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless
a heart exam shows no problem.</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">Do not use Zembrace or Tosymra if you have:</P>

<UL STYLE="margin-top: 0in; list-style-type: disc">

<LI STYLE="text-align: justify; margin: 0">history of heart problems</LI>

<LI STYLE="text-align: justify; margin: 0">narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease)</LI>

<LI STYLE="text-align: justify; margin: 0">uncontrolled high blood pressure</LI>

<LI STYLE="text-align: justify; margin: 0">hemiplegic or basilar migraines. If you are not sure if you have these, ask your provider.</LI>

<LI STYLE="text-align: justify; margin: 0">had a stroke, transient ischemic attacks (TIAs), or problems with blood circulation</LI>

<LI STYLE="text-align: justify; margin: 0">severe liver problems</LI>

<LI STYLE="text-align: justify; margin: 0">taken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan,
naratriptan, rizatriptan, ergotamines, or dihydroergotamine. Ask your provider for a list of these medicines if you are not sure.</LI>

<LI STYLE="text-align: justify; margin: 0">are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has
been 2 weeks or less since you stopped taking a MAO-A inhibitor. Ask your provider for a list of these medicines if you are not sure.</LI>

<LI STYLE="text-align: justify; margin: 0">an allergy to sumatriptan or any of the components of Zembrace or Tosymra</LI>

</UL>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">Tell your provider about all of your medical conditions
and medicines you take, including vitamins and supplements.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">Zembrace and Tosymra can cause dizziness, weakness,
or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert.</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">Zembrace and Tosymra may cause serious side effects
including:</P>

<UL STYLE="margin-top: 0in; list-style-type: disc">

<LI STYLE="text-align: justify; margin: 0">changes in color or sensation in your fingers and toes</LI>

<LI STYLE="text-align: justify; margin: 0">sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation
or diarrhea, bloody diarrhea, fever</LI>

<LI STYLE="text-align: justify; margin: 0">cramping and pain in your legs or hips; feeling of heaviness or tightness in your leg muscles;
burning or aching pain in your feet or toes while resting; numbness, tingling, or weakness in your legs; cold feeling or color changes
in one or both legs or feet</LI>

<LI STYLE="text-align: justify; margin: 0">increased blood pressure including a sudden severe increase even if you have no history of
high blood pressure</LI>

<LI STYLE="text-align: justify; margin: 0">medication overuse headaches from using migraine medicine for 10 or more days each month. If
your headaches get worse, call your provider.</LI>

<LI STYLE="text-align: justify; margin: 0">serotonin syndrome, a rare but serious problem that can happen in people using Zembrace or
Tosymra, especially when used with anti-depressant medicines called SSRIs or SNRIs. Call your provider right away if you have: mental
changes such as seeing things that are not there (hallucinations), agitation, or coma; fast heartbeat; changes in blood pressure; high
body temperature; tight muscles; or trouble walking.</LI>

<LI STYLE="text-align: justify; margin: 0">hives (itchy bumps); swelling of your tongue, mouth, or throat</LI>

<LI STYLE="text-align: justify; margin: 0">seizures even in people who have never had seizures before</LI>

</UL>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">The most common side effects of Zembrace and Tosymra
include: pain and redness at injection site (Zembrace only); tingling or numbness in your fingers or toes; dizziness; warm, hot, burning
feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired; application site (nasal) reactions
(Tosymra only) and throat irritation (Tosymra only).</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">Tell your provider if you have any side effect
that bothers you or does not go away. These are not all the possible side effects of Zembrace and Tosymra. For more information, ask your
provider.</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">This is the most important information to know
about Zembrace and Tosymra but is not comprehensive. For more information, talk to your provider and read the Patient Information and
Instructions for Use. You can also visit https://www.tonixpharma.com or call 1-888-869-7633.</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">You are encouraged to report adverse effects of
prescription drugs to the FDA. Visit&nbsp;www.fda.gov/medwatch, or call 1-800-FDA-1088.</P>

<P STYLE="font: 10pt/115%  Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>

    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>tnxp-20251110.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +6spw7xRiXhun8uCbn1MSayFGbP9w5dz2elBtm96Hel6PyosbKjieC7rSUuGAVUL -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:tnxp="http://tonixpharma.com/20251110" elementFormDefault="qualified" targetNamespace="http://tonixpharma.com/20251110">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://tonixpharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="tnxp-20251110_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="tnxp-20251110_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>tnxp-20251110_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>tnxp-20251110_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20251110.xsd#Cover" roleURI="http://tonixpharma.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tnxp-logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tnxp-logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !  * # 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*^$?\
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MHTT<,;_-#.%.W:"<88X#?@>V#^D]_>6VGV-Q=7DL<%I#&TDTLK (B 98L3P
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:7YMKN&]T&$H"L4VX>4T&5VH0!G(())H _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 10, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 10,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TONIX PHARMACEUTICALS HOLDING CORP.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001430306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-1434750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">26 Main Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Chatham<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(862)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">799-8599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TNXP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tnxp-8k_111025.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>tnxp-20251110.xsd</File>
    <File>tnxp-20251110_lab.xml</File>
    <File>tnxp-20251110_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tnxp-8k_111025.htm">tnxp-8k_111025.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tnxp-8k_111025.htm": {
   "nsprefix": "tnxp",
   "nsuri": "http://tonixpharma.com/20251110",
   "dts": {
    "schema": {
     "local": [
      "tnxp-20251110.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "tnxp-20251110_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tnxp-20251110_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tnxp-8k_111025.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://tonixpharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-11-10",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tnxp-8k_111025.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-11-10",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tnxp-8k_111025.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001999371-25-017369-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001999371-25-017369-xbrl.zip
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M_)M? W1#? *WJ[0TAV/E#L($)&T2*P"@A3"^I>'@.1 ,2.MLG@C(1@ EU2T
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M12\0G&Y:L)=]G,7R"E.@+T! V.L!CF7>1.(<G1 !:[O$ZYL[.QOD^-.BO(Z
M8](/DUA&9)0CJSF"MDU6UL1J0.O3>-D ]5"S-T"@+')E!*/F=W[8;VQ"T?C'
MZ!YQN4[&/T=F%4P9QEP[E'\*]%:MV*],7Y'BJP#OYU!(BCK;[]@FROM'B'>S
M+"FBT_\J,J7,K#;-SJCS25JZ%8>R@5%3PW0?ANO&G')_2//&YCC!=DPI[('
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M$ASP385X@8K.Y.K(#I[2-[T [_<, 9_U9<!G&?"Y 2OOO,;W0P04-_3%@Q:
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MLSGT7K?[<+[NW..BPXNYCKU4<?-?Y#Y,ADMG[PO0BHPH&6G(,_.)+(J3/:T
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M]F9KE6WM[-2V-W9VQE)!'[F_>8YVB^+[*98\9/]4<;>\,:Z3&$@K3H#EW@G
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MM3O5"AQRP#WE.ZR; M)$Q"L# 2P%N$DH'(8M;"*,&1'C&^/[,G3AO+   4^
ML GVJ"=  >RWP#J0(3[H%K5D@&<MX+E^M8+<5B(2U-DD).&'( *3QZ@F63@!
ML<2Z\U-M[ZB"\^(IO Q0=^%!^(Y"KD.'R%$%J793E':\&V+\P41C':NU5"M]
M] ,I&2*&$A9G$]=99RIB(AV@LE56%>SV!> +0+R/K^B!2GV/(2<H-!^01T&
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M3.WB0ETK-C5;Z1RUL4J#"B3-(1LJ-1!Q98S@-CK)@R61#VI7_"@DPNJ2D#0
M6T74@\,S6%6HQU84H\!EV#H*H*AW&?<#915MAPE?Y#_W ,"9"NY4*X"G^6_
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M:I')4*VL9$H)[3-/-T6(Q+$E%3;ZT"+2XB?-P<E@2'[FF*Z">4T4?C%&(.F
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M'5"SX=.#_U#7X2^=K\<?_S]02P,$%     @ 5H-J6_2*$4HF P  ZPL  !$
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M[ E34 Z^;01:;J:FCW\ 4$L#!!0    ( %:#:EN89#;N_0H  '^&   5
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M"X6A=,T%8%5'0Y,%18?=&PA(+??+R))CFB5R .N%Q)0Z/]T S!JG'IHN*$X
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M86_=.YT\NATSGE'FR K*&B7E\XEJF.UG^:B(V[ W7J<3R?W;0RH-H811$KR
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M.E3>W4;MFZ9&L,$O5"S97:A9%TD6ZUP6#K+9HSCO\5<!-8O+D.5WWG= Y^R
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MN@]4%.PSP2;COV^S(B1*\&.R3\ W@!B+"_;_5S"+QKP9.Q9X1;?RYLKOZ=7
M:O !B+JNH3 ()BVR>M(AL7=1F1>66<-[']6)]DP81. 1(FLR7"P7OFVX"&XX
M1$=22I#6O*FW/J7BIDGM$-O5''[PW+((]?N5L&& +05[2<6$O8T-Q-;K03+X
MP;9RK(:WV[KV'\(.3AA (953C1>(:;';0-Z;!#O!FP2 D+U)C]K\57J9N-Q\
M;50W-7XZ7C&IE4*[;%=EI^F2<.2G,/R3>+0'(C< E\QR5J8.3Q>PDOH*8@D
M6_[D\COFR$L4N@222$Y)QJ<DA<K@5M;L5-3B]PHH9!R89QG808IJRZYM@\!@
M CR$E P@VBRK'J@:0,4LFQVI?=5!A4)*$,'_]KE-J+-+=C +$IW9R\DPLL_S
MVAWOW9'4]HX90K;P5?K&7R/D,%U]_9 S#RS\9A$[+_$BCF]S=NIKQ)D/V%8T
M_#6,[OWJBMPR?:JD;UOOC.PJ>QNQNF4VO+QMGFG%<;*0(<5TI&);3J^AS'S;
MZO56W^H_X4IKTTR]>-WW;ZRDP\RW6>_P=?JW_OY"E=@R52V6,\4'LXU[^UME
M_F%]OQ7A"UOI%@P>(^\;5\BD4$@*8FKDZ(E2P=LC\59]312RVW.R+R+T1*G-
M,\N.GUGZZ68EZ(<I/$>,>.5V$V)GITK %V^FH 83.I;Y1=DJ=C#B[S?L,KP*
MRY%9LTPU.'4-_O5HB'T_&E+\EX3WXB_S?TZI$5UEO] RDOYI&?W3,MI>RVC+
M[[!T&^?-<N^F4_N,N\K1_K;X71!>=_[)5:EW<\L<[*QQL+._?!N9=?455YLB
M&;NL$\_/>/RO60 L?8)LH L&3.]5\3X986W :F@&B-\"\R>P\R[B&HZYP^%A
MUQF9%$Q$V4!-/>],O[_26<"Z5@'YP7+;\\)YQ1VYU0$PEF"=)#*;O@FTSO<3
MO/D2RYMY6G;FMX%?B@\Y8:,5/?MNC6+41A]?#?J$9#=*QRFL6>-B0FR%$=3*
MF8U2E;;3Z)1B12-3< X"882N(1E.Q,>4_HE^\@)_7YOPRD@E@X5&=XN_9A7-
MP"9RPI5KKY]UR)CY)V-\0V+T2G*TSI>U'I[>\\-\[R6DV7>\DHO)V8,B7 X?
MR]]'/]-E9?(@M?3)CT/[ZLJJ7$YK#<-4[,>)9G3J/ZD\J.?U3/^LI?YU6_FK
M1>2#QF'GNG^N.K?2]^Q5WJX\. \BO6LTSGK]!JX<F/6!)FG9\\'9C[RHX.GU
M>4$>Z!=-0Z@V+;TR2M=S0KO?K[<:#:I?6T:]DCNU+D;79F%ZE<T_Z#\[CF(:
M9W\YEV?-ZE3I_NH\*5G]]+*5?[P]=_7ZH5*[E'1SVJ[\>?/X/#V_O?D^KI.G
MH7$HBY4;\EW5&\(/M9SI/0^(*\KNZ,^?EV-,Z[\._IS4TK^>L^7K$>UJ\HDG
MD33[:EK^K<>.KI7^!U!+ 0(4 Q0    ( %:#:EO0VE:T##8   5> 0 +
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F>' M.&M?,3$Q,#(U+FAT;5!+!08     !0 % #X!  "^70     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>tnxp-8k_111025_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tnxp-20251110.xsd" xlink:type="simple"/>
    <context id="AsOf2025-11-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
        </entity>
        <period>
            <startDate>2025-11-10</startDate>
            <endDate>2025-11-10</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-11-10" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-11-10" id="Fact000004">0001430306</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-11-10" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-11-10" id="Fact000010">2025-11-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-11-10" id="Fact000011">TONIX PHARMACEUTICALS HOLDING CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-11-10" id="Fact000012">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-11-10" id="Fact000013">001-36019</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-11-10" id="Fact000014">26-1434750</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-11-10" id="Fact000015">26 Main Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-11-10" id="Fact000016">Chatham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-11-10" id="Fact000017">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-11-10" id="Fact000018">07928</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-11-10" id="Fact000019">(862)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-11-10" id="Fact000020">799-8599</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-11-10" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-11-10" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-11-10" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-11-10" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-11-10" id="Fact000025">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-11-10" id="Fact000026">TNXP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-11-10" id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-11-10" id="Fact000028">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
